ProShares Ultra NASDAQ Biotechnology
23 hedge funds and large institutions have $3.6M invested in ProShares Ultra NASDAQ Biotechnology in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
459% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $204K
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
70% more capital invested
Capital invested by funds: $2.12M → $3.6M (+$1.48M)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
21% more funds holding
Funds holding: 19 → 23 (+4)
1.9% more ownership
Funds ownership: 2.53% → 4.43% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$631K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$561K |
| 3 |
CAG
Csenge Advisory Group
Clearwater,
Florida
|
+$237K |
| 4 |
ATPW
Ashton Thomas Private Wealth
Scottsdale,
Arizona
|
+$30.9K |
| 5 |
DWP
Destiny Wealth Partners
Tavares,
Florida
|
+$22.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$64K |
| 2 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$16.3K |
| 3 |
WT
Whittier Trust
South Pasadena,
California
|
-$4.97K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$249 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$83 |
BIB Hedge Fund Activity: Q1 2026 in Review
23 of the 8,203 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2026, worth a combined $3.6M — up 70% from $2.12M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BIB positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $631K. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $64K sold.
- 23 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2026, up from 19 in Q4 2025.
- Funds reported $3.6M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2026, up 70% quarter-over-quarter.
- 6 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2026 and 2 closed out, a net change of +4 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2026 was Citadel Advisors, an estimated $631K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2026 was Royal Bank of Canada, an estimated $64K sold.
Based on aggregated 13F filings for Q1 2026.